Thyme Care Secures $97M Series D Funding, Expands Cancer Care Navigation Services

Thyme Care, a value-based cancer care navigation company, has raised $97 million in a Series D funding round, propelling its valuation to over $1 billion. The investment, backed by major strategic players across the healthcare spectrum, aims to accelerate the company's growth and enhance its oncology support services.

Strategic Investors and Expansion Plans

The latest funding round includes both current and new strategic investors, signaling strong industry confidence in Thyme Care's approach. CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures continued their support. New investors joining the round include Morgan Health (JPMorgan Chase's employer-sponsored healthcare unit), Humana, Texas Oncology, and Memorial Hermann Health System.

Robin Shah, CEO and co-founder of Thyme Care, emphasized the company's plans to expand across verticals and address critical issues in the oncology journey. "We're accelerating investments in technology and AI to enhance care delivery, and scaling our partnerships across the ecosystem to reach more people with more support," Shah stated.

Service Expansion and Technological Advancements

Thyme Care is focusing on tackling treatment denials, high drug costs, and barriers to timely and affordable care. The company plans to hire tech leaders to advance its AI platform strategy, aiming to develop more member-facing apps and tech solutions for its care team.

The company's hybrid collaborative care model integrates with over 1,000 oncologists through Thyme Care Oncology Partners. This approach combines 24/7 specialized cancer care navigation services, technology, data insights, and oncologist-led therapeutic interventions.

Impressive Growth and Impact

Since its founding in 2020, Thyme Care has rapidly scaled its operations. The company now manages 80,000 actively treated cancer patients, up from 10,000 at the end of 2024. It oversees more than $5 billion in oncology spend and has achieved profitability.

Thyme Care's services have demonstrated significant benefits:

• 40% reduction in emergency room visits
• 19% decrease in hospital admissions
• 90% of members report feeling more supported by their care team
• 72% of members respond to proactive patient-reported outcome surveys

The company's partnerships span Medicare, commercial, and employer contracts, making its services accessible to 8 million people. National partnerships include major payers such as Aetna and Humana, Fortune 500 employers, and leading health systems.

As Thyme Care continues to grow, it aims to provide a blueprint for scalable, accountable cancer care and serve as a proving ground for value-based care in oncology.